Allogene Therapeutics (ALLO) Gets a Hold Rating from J.P. Morgan

J.P. Morgan analyst Cory Kasimov maintained a Hold rating on Allogene Therapeutics (ALLOResearch Report) on February 24 and set a price target of $24.00. The company’s shares closed last Friday at $8.04, close to its 52-week low of $7.97.

According to TipRanks.com, Kasimov is a 5-star analyst with an average return of 18.0% and a 54.3% success rate. Kasimov covers the Healthcare sector, focusing on stocks such as Cerevel Therapeutics Holdings, Ultragenyx Pharmaceutical, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Allogene Therapeutics is a Moderate Buy with an average price target of $24.57, representing a 189.1% upside. In a report issued on February 25, Goldman Sachs also maintained a Hold rating on the stock with a $12.00 price target.

See today’s best-performing stocks on TipRanks >>

Based on Allogene Therapeutics’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $49K and GAAP net loss of $78.19 million. In comparison, last year the company had a GAAP net loss of $68.57 million.

Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ALLO in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Allogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.

Read More on ALLO:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed